Download PDF
Semin Respir Crit Care Med
DOI: 10.1055/a-2578-4335
Review Article

Clinical Course and Outcomes in Patients with Sjögren's Associated Interstitial Lung Disease

Prachi Saluja‡   *
1   Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio
,
Joanna L. Marco‡   *
2   Division of Rheumatology, Allegheny Health Network, Pittsburgh, Pennsylvania
,
Nitesh Gautam
3   Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
,
Christine L. Chhakchhuak
4   Division of Rheumatology, Allergy and Immunology, University of Cincinnati, Cincinnati, Ohio
5   Medical Service, Veterans Affairs Medical Center, Cincinnati, Ohio
,
Gregory C. Gardner
6   Division of Rheumatology, University of Washington, Seattle, Washington
,
Nishant Gupta
1   Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio
5   Medical Service, Veterans Affairs Medical Center, Cincinnati, Ohio
› Author Affiliations
Funding None.
› Further Information
   Permissions and Reprints

Abstract

Background

Lung involvement in Sjögren's disease (SjD) is common and significantly impacts patients' quality of life, with the most frequent manifestation being interstitial lung disease (ILD). This study explored the clinical course and prognostic factors in patients with SjD-associated ILD.

Methods

We conducted a retrospective analysis of patients diagnosed with SjD-ILD across two tertiary care academic referral centers. We assessed key clinical, radiological, and histopathological features of patients with SjD-ILD to investigate the long-term outcomes and determine the factors that can help better prognosticate patients in the clinic.

Results

A total of 81 patients with SjD-ILD were included in our analysis. ILD was the presenting manifestation in 21% (n = 17) of the SjD patients. The median survival following diagnosis of SjD-ILD was 11 years. Among ILD subtypes, the UIP pattern was associated with more rapid lung function decline and higher mortality. In contrast, higher baseline forced vital capacity (FVC) and anti-SSA antibody positivity were linked to reduced mortality risk.

Conclusion

ILD is a common manifestation that can lead to the diagnosis of SjD. The presence of ILD has an adverse effect on the overall survival of patients with SjD. Baseline lung function and serologies can further assist in prognostication. A critical review of imaging patterns to determine the underlying ILD pattern can aid individualized counseling and therapeutic decision-making in patients with SjD-ILD.

Keywords

Sjögren's disease - interstitial lung disease - outcome

Authors' Contributions

P.S.: Data analysis and writing.


J.M.: Methodology and data acquisition.


N.G.: Data analysis.


C.C. and G.G.: Writing and supervision.


Nishant Gupta: Conceptualization, methodology, writing, and supervision.


All authors contributed substantially to the writing and editing of the manuscript and have approved the final version for submission.


* Contributed equally to this work.




Publication History

Article published online:
30 May 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Shiboski CH, Shiboski SC, Seror R. et al; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League against rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69 (01) 35-45
    CrossrefPubMedSearch in Google Scholar
  • 2 Luppi F, Sebastiani M, Silva M. et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol 2020; 38 (4, suppl 126): 291-300
    PubMedSearch in Google Scholar
  • 3 Mariette X, Criswell LA. Primary Sjögren's syndrome. N Engl J Med 2018; 378 (10) 931-939
    PubMedSearch in Google Scholar
  • 4 Lee AS, Scofield RH, Hammitt KM. et al; Consensus Expert Panel (CEP) Members. Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's. Chest 2021; 159 (02) 683-698
    CrossrefPubMedSearch in Google Scholar
  • 5 Lin W, Xin Z, Zhang J. et al. Interstitial lung disease in Primary Sjögren's syndrome. BMC Pulm Med 2022; 22 (01) 73
    CrossrefPubMedSearch in Google Scholar
  • 6 Weng L, Chen Y, Liang T. et al. Biomarkers of interstitial lung disease associated with primary Sjögren's syndrome. Eur J Med Res 2022; 27 (01) 199
    CrossrefPubMedSearch in Google Scholar
  • 7 Byrne L, McCarthy C, Fabre A, Gupta N. Pulmonary manifestations of Sjögren's disease. Semin Respir Crit Care Med 2024; 45 (03) 397-410
    PubMedSearch in Google Scholar
  • 8 Guo T, Long Y, Shen Q. et al. Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients. Ann Med 2021; 53 (01) 1340-1348
    PubMedSearch in Google Scholar
  • 9 Sogkas G, Hirsch S, Olsson KM. et al. Lung involvement in primary Sjögren's syndrome-an under-diagnosed entity. Front Med (Lausanne) 2020; 7: 332
    PubMedSearch in Google Scholar
  • 10 Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sjögren syndrome-associated interstitial lung disease. Sci Rep 2021; 11 (01) 12827
    CrossrefPubMedSearch in Google Scholar
  • 11 Enomoto Y, Takemura T, Hagiwara E. et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 2013; 8 (09) e73774
    CrossrefPubMedSearch in Google Scholar
  • 12 Kamiya Y, Fujisawa T, Kono M. et al. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. Respir Med 2019; 159: 105811
    CrossrefPubMedSearch in Google Scholar
  • 13 He S-H, He Y-J, Guo K-J, Liang X, Li S-S, Li T-F. Risk factors for progression of interstitial lung disease in Sjögren's syndrome: a single-centered, retrospective study. Clin Rheumatol 2022; 41 (04) 1153-1161
    PubMedSearch in Google Scholar
  • 14 Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130 (05) 1489-1495
    CrossrefPubMedSearch in Google Scholar
  • 15 M. Makara, N. Gupta, L. Destro, J. Church. K.M. Hammitt. Respiratory Symptoms and Disease in Sjögren's: Patient Experience and Impact on Quality of Life [abstract]. Am J Respir Crit Care Med 2024; 209: A2741
    PubMedSearch in Google Scholar
  • 16 Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013; 12 (11) 1076-1084
    PubMedSearch in Google Scholar
  • 17 Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse cystic lung disease as the presenting manifestation of Sjögren syndrome. Ann Am Thorac Soc 2016; 13 (03) 371-375
    CrossrefPubMedSearch in Google Scholar
  • 18 Lee KA, Nam BD, Hwang JH, Kim HS. Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren's syndrome. Sci Rep 2023; 13 (01) 9189
    PubMedSearch in Google Scholar
  • 19 Roca F, Dominique S, Schmidt J. et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev 2017; 16 (01) 48-54
    CrossrefPubMedSearch in Google Scholar
  • 20 Sambataro G, Ferro F, Orlandi M. et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev 2020; 19 (02) 102447
    CrossrefPubMedSearch in Google Scholar
  • 21 Alhamad EH, Cal JG, Alrajhi NN. et al. Clinical characteristics and outcomes in patients with primary Sjogren's syndrome-associated interstitial lung disease. Ann Thorac Med 2021; 16 (02) 156-164
    PubMedSearch in Google Scholar
  • 22 Manfredi A, Sebastiani M, Cerri S. et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol 2017; 36 (06) 1261-1268
    PubMedSearch in Google Scholar
  • 23 Selman M, Pardo A, Wells AU. Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift?. Lancet Respir Med 2023; 11 (02) 188-196
    PubMedSearch in Google Scholar
  • 24 Behr J, Prasse A, Kreuter M. et al; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9 (05) 476-486
    CrossrefPubMedSearch in Google Scholar
  • 25 Gonçalves CM, Cordeiro LR, de Andrade CAF, de Carvalho JF. Lymphocytic interstitial pneumonia associated with Sjögren syndrome: case-based review. Curr Rheumatol Rev 2023; 19 (01) 1-6
    PubMedSearch in Google Scholar
  • 26 Chen J, He Q, Yang J. et al. Anti-SSA/SSB-negative primary Sjögren's syndrome showing different clinical phenotypes: a retrospective study of 934 cases. Adv Rheumatol 2023; 63 (01) 21
    PubMedSearch in Google Scholar